标题：Genistein inhibits human papillary thyroid cancer cell detachment, invasion and metastasis
作者：Zhang, Chunyan; Lv, Bin; Yi, Cuihua; Cui, Xiujie; Sui, Shaofeng; Li, Xueen; Qi, Mei; Hao, Chunyan; Han, Bo; Liu, Zhiyan
作者机构：[Zhang, Chunyan; Cui, Xiujie; Hao, Chunyan; Liu, Zhiyan] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, 44 WenhuaXi Rd,Lixia Area, J 更多
通讯作者：Liu, ZY;Liu, ZY
通讯作者地址：[Liu, ZY]Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, 44 WenhuaXi Rd,Lixia Area, Jinan 250012, Shandong, Peoples R China;[Liu, ZY] 更多
来源：JOURNAL OF CANCER
关键词：Genistein; Papillary thyroid carcinoma; Proliferation; Epithelial; mesenchymal transition; BRAF(v600E) mutation
摘要：Papillary thyroid carcinoma (PTC) is the most commonly diagnosed endocrine cancer, and those with BRAF(v600E) mutation have high recurrence rate and less favorable clinical behavior. Genistein having anti-carcinoma effects in various types of carcinomas as an estrogen analog, but the mechanism of Genistein in the progression of PTC remains unknown. Genistein significantly inhibits the proliferation and the invasion (P < 0.01), and the apoptosis (P < 0.001) of all tumor cell lines, which was probably due to the inducing of the arrest in G2/M phase of the cell cycle (P < 0.001). The anti-proliferation and apoptosis inducing effects are more obvious in BCPAP, IHH4 cell lines harboring BRAF(v600E) mutation. Genistein significantly decreased the invasion of PTC cell lines and partially reverses epithelial mesenchymal transition in PTC cell lines. Functional study indicated that small interfering RNA (siRNA) knockdown of beta-catenin significantly reverses the effect of genistein on EMT at protein levels. In conclusion, for the first time, our study suggested that genistein has anticarcinoma effect for PTC patients in the range of 2.5 and 80 mu g/ml in thyroid carcinoma cells, which was probably through cytoplasmic translocation of beta-catenin. Further study will be needed to determine whether genistein could be used in clinical trial of high-risk PTC.